Home › Cirrhosis › NCT06015022

EGCG for Hepatocellular Carcinoma Chemoprevention

Phase II Randomized Controlled Trial of Epigallocatechin Gallate for Hepatocellular Carcinoma Chemoprevention

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults (≥ 18 years-old)
* Clinically and/or histologically diagnosed cirrhosis
* No active hepatic decompensation
* No prior history of HCC
* Adequate hematologic, hepatic, and renal function
* Karnofsky performance status score ≥70
* Both sexes and all racial/ethnic groups will be considered
* FIB-4 index \> 3.25
* High-risk PLSec at baseline
* Absence of HLA-B\*35:01

Exclusion Criteria:

* Prior or ongoing use of EGCG
* History of adverse reaction to green tea products
* Severe obesity (BMI \> 40 kg/m2)
* Active drinking
* EGCG treatment \<4 weeks or \<80% of planned regimen at the end of week 4
* HCC development during the study

About the study

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

What is being tested

• Epigallocatechin gallate (EGCG) (drug)
• Placebo (other)

Sponsor: University of Texas Southwestern Medical Center · Participants: 60 · Started: Sep 1, 2024

Contact the study team

• Yujin Hoshida, MD, PhD · Phone: 214-648-3111

Official record on ClinicalTrials.gov — NCT06015022

Locations in the U.S.

Conditions

• Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)
• Liver Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.